ArticlePloS one2026
Loss of IL1RA promotes prostate cancer growth and metastasis by activating Akt signaling pathway.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundInterleukin-1 receptor antagonist (IL1RA) blocks the interaction between IL-1 and its receptors. It modulates inflammatory responses, cell proliferation, and the invasion of cancer cells. In this study, we examined the biological functions of IL1RA and the mechanisms that influence its effects on prostate cancer (PCa). MATERIALS AND
methodsWe performed RT-qPCR and Western blot analyses to evaluate IL1RA expression levels in various cell lines. For functional studies, we employed MTT, colony formation, soft agar, wound healing, and transwell migration and invasion assays. Then, we analyzed Western blots to elucidate the underlying mechanisms involved. Xenograft mouse models were ultimately established after the overexpression of IL1RA.
resultsIL1RA was expressed at higher levels in prostate epithelial cells compared with the PCa cell lines. BPH cells with lower IL1RA expression exhibited an increased cell proliferation. The PCa cell lines C4-2B and LNCap, which overexpressed IL1RA, demonstrated suppressed tumorigenic properties in vitro. The in vivo experiment demonstrated an inhibitory effect on tumor growth in xenograft mice. Furthermore, Western blot results indicated elevated phosphorylated AKT levels in BPH cells with IL1RA knockdown, and phosphorylated AKT and GSK-3[Formula: see text] levels were reduced in C4-2B and LNCap cells that overexpressed IL1RA.
conclusionThis study revealed that IL1RA low expression is associated with PCa progression. Our finding has great clinical and translational significance. The potential clinical application of IL1RA as a therapeutic target for PCa requires further investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.